SLG
UTHR icon

Stanley-Laman Group’s United Therapeutics UTHR Stock Holding History

Stanley-Laman Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-59,582
Closed -$7.67M – 318
2014
Q3 		$7.67M Sell
59,582
-1,573
-3% -$162K 1.49% 8
2014
Q2 		$5.41M Sell
61,155
-828
-1% -$79.6K 0.99% 31
2014
Q1 		$5.83M Buy
+61,983
New +$6.34M 1.02% 25

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Stanley-Laman Group's UTHR Position: Q4 2014 in Review

Stanley-Laman Group sold out of United Therapeutics (UTHR) in Q4 2014, closing a stake of 59,582 shares — an estimated $7.67M sold.

Stanley-Laman Group first reported a position in UTHR in Q1 2014 and held it in 3 quarters. The position peaked at $7.67M in Q3 2014. 334 funds tracked by Wall St. Rank hold UTHR as of Q4 2014.

  • Stanley-Laman Group reported no remaining United Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Stanley-Laman Group sold 59,582 United Therapeutics shares in Q4 2014, an estimated $7.67M.
  • Stanley-Laman Group first reported a position in United Therapeutics in Q1 2014 and held it in 3 quarters.
  • Stanley-Laman Group's United Therapeutics position peaked at $7.67M in Q3 2014.
  • 334 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2014.

Based on Stanley-Laman Group's 13F filing for Q4 2014, filed 30 Jan 2015.